Profile data is unavailable for this security.
About the company
Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
- Revenue in USD (TTM)521.00k
- Net income in USD-152.10m
- Incorporated2014
- Employees121.00
- LocationMorphic Holding Inc35 GATEHOUSE DRIVE A2WALTHAM 02451United StatesUSA
- Phone+1 (781) 996-0955
- Fax+1 (302) 655-5049
- Websitehttps://morphictx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.27bn | 267.00 | -- | -- | -- | 2.86 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Soleno Therapeutics Inc | 0.00 | -38.99m | 1.31bn | 33.00 | -- | 7.91 | -- | -- | -2.97 | -2.97 | 0.00 | 4.97 | 0.00 | -- | -- | 0.00 | -37.64 | -53.90 | -41.40 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
| Novocure Ltd | 509.34m | -207.04m | 1.32bn | 1.45k | -- | 3.65 | -- | 2.59 | -1.95 | -1.95 | 4.79 | 3.39 | 0.4358 | 3.80 | 6.91 | 350,542.30 | -17.71 | -7.74 | -20.71 | -8.95 | 74.81 | 77.22 | -40.65 | -14.69 | 5.56 | -- | 0.6108 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -188.92m | 1.33bn | 155.00 | -- | 3.82 | -- | -- | -2.37 | -2.37 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.11 | -- | -55.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Gyre Therapeutics Inc | 0.00 | -44.24m | 1.37bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 486.82m | 15.48m | 1.37bn | 642.00 | 79.70 | 3.10 | 17.84 | 2.82 | 0.821 | 0.821 | 26.17 | 22.35 | 0.5849 | 1.68 | 2.97 | 758,280.40 | 2.26 | -2.83 | 2.65 | -3.35 | 62.71 | 60.18 | 3.86 | -6.15 | 2.81 | 1.79 | 0.3843 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Morphic Holding Inc | 521.00k | -152.10m | 1.39bn | 121.00 | -- | 1.98 | -- | 2,659.37 | -3.49 | -3.49 | 0.0119 | 14.01 | 0.001 | -- | 2.29 | 4,305.79 | -27.88 | -22.69 | -28.99 | -24.99 | -- | -- | -29,192.90 | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Akero Therapeutics Inc | 0.00 | -151.76m | 1.39bn | 55.00 | -- | 2.11 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
| Arcus Biosciences Inc | 117.00m | -307.00m | 1.40bn | 577.00 | -- | 2.52 | -- | 11.98 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Tilray Brands Inc | 743.25m | -351.95m | 1.42bn | 1.60k | -- | 0.424 | -- | 1.92 | -0.4979 | -0.4979 | 1.04 | 4.34 | 0.1731 | 2.39 | 8.85 | 464,530.00 | -7.61 | -- | -8.38 | -- | 28.01 | -- | -43.98 | -- | 1.18 | 0.2252 | 0.1216 | -- | -0.1986 | -- | -204.67 | -- | -- | -- |
| Kura Oncology Inc | 0.00 | -152.63m | 1.43bn | 142.00 | -- | 3.51 | -- | -- | -2.08 | -2.08 | 0.00 | 5.34 | 0.00 | -- | -- | 0.00 | -33.72 | -26.04 | -36.09 | -27.45 | -- | -- | -- | -- | -- | -- | 0.023 | -- | -- | -- | -12.36 | -- | -- | -- |
| Dynavax Technologies Corp | 232.28m | -6.39m | 1.49bn | 408.00 | -- | 2.38 | -- | 6.43 | -0.0733 | -0.0733 | 1.65 | 4.80 | 0.2343 | 0.89 | 2.50 | 569,323.50 | -0.6444 | 4.16 | -0.7216 | 5.71 | 78.40 | 64.83 | -2.75 | 9.19 | 12.96 | -- | 0.2636 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Ardelyx Inc | 124.46m | -66.07m | 1.50bn | 267.00 | -- | 8.96 | -- | 12.02 | -0.3038 | -0.3038 | 0.5643 | 0.7176 | 0.5104 | 2.26 | 8.36 | 466,127.30 | -27.10 | -46.14 | -35.55 | -57.32 | 85.70 | 88.15 | -53.08 | -240.87 | 4.64 | -12.70 | 0.23 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| ADMA Biologics Inc | 258.22m | -28.24m | 1.50bn | 624.00 | -- | 10.80 | -- | 5.80 | -0.1263 | -0.1263 | 1.14 | 0.5981 | 0.7621 | 1.01 | 12.03 | 413,806.10 | -8.33 | -24.80 | -9.60 | -28.00 | 34.44 | 17.02 | -10.94 | -51.31 | 1.69 | 0.924 | 0.4913 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Protagonist Therapeutics Inc | 60.00m | -78.96m | 1.50bn | 112.00 | -- | 4.41 | -- | 24.96 | -1.47 | -1.47 | 1.06 | 5.83 | 0.1981 | -- | 11.56 | 535,714.30 | -26.06 | -35.90 | -28.53 | -41.36 | -- | -- | -131.59 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.50bn | 88.00 | -- | 3.56 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Data as of Apr 24 2024. Currency figures normalised to Morphic Holding Inc's reporting currency: US Dollar USD
58.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 6.78m | 13.56% |
| Point72 Asset Management LPas of 31 Dec 2023 | 4.59m | 9.18% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 3.38m | 6.75% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.81m | 5.62% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.56m | 5.12% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.23m | 4.46% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.18m | 4.35% |
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 2.14m | 4.27% |
| Pictet Asset Management SAas of 31 Dec 2023 | 1.79m | 3.58% |
| Federated Global Investment Management Corp.as of 31 Dec 2023 | 1.00m | 2.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
